Wide-Spread Unappreciated Alpha-Synuclein Aggregates in CNS - a Cause of Symptoms, Caution and Optimism in Parkinson's Disease and Lewy Body Dementia

Attend a keynote webinar exploring the widespread presence of alpha-synuclein aggregates in the central nervous system and their role in Parkinson's disease and Lewy body dementia. Learn from Prof. Poul Henning Jensen, a leading expert in alpha-synuclein biology with over 135 published research papers, as he presents groundbreaking research on synucleinopathies. Discover how Parkinson's disease belongs to a group of conditions characterized by progressive aggregation of the neuronal protein alpha-synuclein, traditionally diagnosed through the loss of dopaminergic neurons and presence of Lewy bodies. Examine recent data revealing that alpha-synuclein aggregates affect wider areas of the nervous system than previously appreciated through conventional immunohistochemical staining, with these aggregates now detectable in biofluids. Understand how these less appreciated non-Lewy body aggregates indicate that Parkinson's disease initiates long before clinical diagnosis and impacts nervous tissue on a much larger anatomical scale than anticipated. Explore the implications of these findings for newly proposed biological staging systems for Parkinson's disease and Lewy body dementia, and consider how the presence of aggregates in apparently unaffected neurons suggests high toxicity while potentially contributing to symptomatology by disrupting neuronal circuitries. Gain insights into how these discoveries open new avenues for symptomatic treatments and disease-modifying strategies. Participate in a live Q&A session with the presenter and earn PACE credits through Labroots' accredited program.